|Day Low/High||21.80 / 23.02|
|52 Wk Low/High||18.41 / 32.90|
With the Fed and the healthcare vote out of the way, markets will focus on earnings in the week ahead.
Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.
-- Study Results Further Support Advancement of SYN-005 into Clinical Trials for Treatment and Prevention of Pertussis --
Doug Kass shares his thoughts on Apple, Allergan and Western Digital.
Jim Cramer says Pfizer needs to do a deal and buy someone; and he thinks Raytheon is a terrific stock.
Doug Kass shares his thoughts on Twitter and talks about Sears.
Geno Germano to Step Down as President; Randal Kirk to Remain CEO
Saudi Aramco will assume control of the biggest oil refinery in the U.S. after a $2.2 billion deal with Shell that exits a joint venture in Port Arthur, Texas.
The most recent short interest data was recently released for the 01/31/2017 settlement date, and Intrexon Corp is one of the most shorted stocks of the Russell 3000, based on 11.99 "days to cover" versus the median component at 5.13. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intrexon Corp , where a total of 12,560 contracts have traded so far, representing approximately 1.3 million underlying shares. That amounts to about 99.4% of XON's average daily trading volume over the past month of 1.3 million shares.
Here's how to rake in the gains off some potential big breakouts.
GenVec's AdenoVerse™ to be Integrated into Intrexon's Proprietary Synthetic Biology Platform
Doug Kass shares his thoughts on buying retail, and discusses why he's favoring the short side in a big way.